- Price
- $110.40
- Day
- +4.13%
- Mkt Cap
- $4.61B
- 52W Range
- $18.08 – $114.55
- Volume
- 622.5K
- Beta
- 0.08
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees.
Read full article